CoreValve Prevails in United Kingdom Patent Infringement Action

2009-01-09 17:37:02 -

CoreValve (www.corevalve.com) announced today that it has prevailed in a patent infringement lawsuit with Edwards Lifesciences in the United Kingdom.


The High Court of Justice, Chancery Division, found that CoreValve's ReValving® system for transcatheter aortic valve replacement does not infringe any of the claims of the Andersen patent held by Edwards. The U.K. court joins the Regional Court of Düsseldorf, which rendered a decision in October 2008, in finding that Edwards' European Andersen patent does not cover CoreValve's ReValving system. Because Edwards has only filed European lawsuits in the U.K. and Germany, these rulings protect patient access to CoreValve's proprietary system for percutaneous aortic valve replacement in high-risk patients with advanced aortic valve disease throughout Europe.


"We are gratified by the decision in the U.K. court. While an appeal of this ruling is possible, we will continue to vigorously defend our own intellectual property and our legal right to continue to clinically evaluate and market our ReValving system for the treatment of patients worldwide. Last year more than 2,000 patients outside the United States received a CoreValve ReValving system, and we hope twice as many patients will be treated with our technology in 2009," said Daniel Lemaitre, CoreValve's President and Chief Executive Officer.


About CoreValve


CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving® System allows percutaneous aortic valve replacement (PAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at www.corevalve.com.


(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)





Ronald Trahan Associates Inc.

Ronald Trahan, 508-359-4005, x108

APR